Compare Boston Scientific Corporation (BSX) vs National Beverage Corp. (FIZZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs National Beverage Corp. — how do they compare? Boston Scientific Corporation trades at $51.56 (market cap $74.19B), while National Beverage Corp. trades at $30.9 (market cap $2.89B). The key difference: Boston Scientific Corporation is far larger — about 25.7× National Beverage Corp.'s market cap, and Boston Scientific Corporation is trading nearer its 52-week high, National Beverage Corp. nearer its low. Which is the better fit depends on your goals.
| BSX | FIZZ | |
|---|---|---|
Market Cap | $74.19B | $2.89B |
Sector | Health | Consumer Cyclical |
52-Week High | $108.14 | $46.75 |
52-Week Low | $42.63 | $30.53 |
Enterprise Value | $86.27B | $2.60B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $51.66, up 2.38% today, showing strong momentum with three consecutive quarterly earnings beats. The stock maintains bullish technical signals with moving averages supporting upward movement, though oscillators indicate potential overbought conditions. Fundamentally, BSX demonstrates robust growth with 2025 revenue reaching $20.07B and net income margin expanding to 14.43%, supported by strong cash flow generation of $1.54B in 2025.
The outlook remains positive with 86% analyst buy ratings and a $67.21 consensus price target offering 30% upside potential. Key risks include competitive pressures in WATCHMAN and electrophysiology segments, along with recent guidance cuts. Insider buying by the CEO and director signals management confidence in the company's long-term prospects despite near-term challenges.
FIZZ trades at $30.95, down 0.29% on the day, with a bearish technical signal from moving averages and a neutral stance from oscillators. Revenue has been stable around $1.2B annually, with net income margins improving to 15.56% in 2025. Recent earnings have missed expectations in three of the last four quarters, while the company declared a special dividend of $3.25 per share payable in July 2026.
The outlook is mixed; strong profitability and a reasonable P/E of 15.73 offer value, but stagnant growth and bearish analyst consensus pose risks. The stock's performance hinges on reversing earnings misses and addressing competitive pressures in the beverage market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About National Beverage Corp.
National Beverage Corp is one of the top 10 non-alcoholic beverage companies in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls most of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for big-box retailers, direct-store-delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants). It is controlled by chairman and CEO Nick Caporella, who owns over 73% of the common stock.
Read more on FIZZ →
